AXSM Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc. (AXSM) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 100% planned / 0% discretionary
Largest single sale: $11.9M.
Where they traded
Last open-market purchase: September 8, 2025 — 1.0 years ago, by Coleman Mark .
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Jacobson Mark L. | Chief Operating Officer | Sell 10b5-1 | 10,000 | $208.65 | $2.1M | None left | |
| TABUTEAU HERRIOT | Chief Executive Officer | Sell 10b5-1 | 4,660 | $213.95 | $997.0K | 7,229 −39.2% of holding | |
| TABUTEAU HERRIOT | Chief Executive Officer | Sell 10b5-1 | 45,004 | $212.01 | $9.5M | 7,229 −86.2% of holding | |
| TABUTEAU HERRIOT | Chief Executive Officer | Sell 10b5-1 | 49,666 | $240.25 | $11.9M | 7,229 −87.3% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.